First Quadrant’s Fortress Biotech FBIO Stock Holding History

First Quadrant’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-880	Closed	-$47K	–	526
2021 Q2	$47K	Buy	+880	New	+$53.1K	0.01%	404

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Quadrant's FBIO Position: Q3 2021 in Review

First Quadrant sold out of Fortress Biotech (FBIO) in Q3 2021, closing a stake of 880 shares — an estimated $47K sold.

First Quadrant first reported a position in FBIO in Q2 2021 and held it in 1 quarter. The position peaked at $47K in Q2 2021. 79 funds tracked by Wall St. Rank hold FBIO as of Q3 2021.

First Quadrant reported no remaining Fortress Biotech position as of Q3 2021 after selling out during the quarter.
First Quadrant sold 880 Fortress Biotech shares in Q3 2021, an estimated $47K.
First Quadrant first reported a position in Fortress Biotech in Q2 2021 and held it in 1 quarter.
First Quadrant's Fortress Biotech position peaked at $47K in Q2 2021.
79 funds tracked by Wall St. Rank held Fortress Biotech as of Q3 2021.

Based on First Quadrant's 13F filing for Q3 2021, filed 26 Oct 2021.